CLINICAL TRIALS PROFILE FOR LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01348243 ↗	Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis	Completed	Chiesi Farmaceutici S.p.A.	Phase 3	2011-10-01	Clodronic acid 100 mg/3,3 ml is used to prevent and treat postmenopausal osteoporosis. The intramuscular formulation, which is given at a dose of 100 mg every 7 o 14 days, is at least as effective as daily oral therapy and appears more effective than intermittent intravenous treatment. Intramuscular clodronic acid in particular has also been associated with improvements in back pain. The drug is well tolerated, with no deleterious effects on bone mineralization, and use of parenteral therapy eliminates the risk of gastrointestinal adverse effects that may be seen in patients receiving oral bisphosphonates therapy. In order to simplify the therapeutic dosing regimen, reducing the number of administrations per month, and therefore increase adherence to bisphosphonates therapy of the patient, a new formulation of disodium clodronic acid containing 200 mg/4 mL for i.m. administration has been developed. Lidocaine in this new formulation, as local anaesthetic, is maintained at the same concentration as in the 100 mg clodronic acid formulation. The pharmacokinetics and tolerability of the intramuscular formulation of clodronic acid 200 mg in comparison to the marketed formulation clodronic acid 100 mg was evaluated in healthy post-menopausal volunteers. Two formulations were similar in terms of amount and rate of clodronic acid urinary excretion and in terms of safety profile.
OTC	NCT02229539 ↗	Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	2014-11-01	The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. This study will evaluate the effects of doxepin compared to DLA (diphenhydramine, lidocaine and antacids) and placebo.Doxepin is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety, long-term pain management, as well as management of rash.
OTC	NCT02229539 ↗	Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy	Completed	Alliance for Clinical Trials in Oncology	Phase 3	2014-11-01	The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. This study will evaluate the effects of doxepin compared to DLA (diphenhydramine, lidocaine and antacids) and placebo.Doxepin is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety, long-term pain management, as well as management of rash.
OTC	NCT02749123 ↗	Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis	Unknown status	J.A.R. Laboratories	N/A	2016-04-01	A comparison of transdermal patches for efficacy, side effects and quality of life for patients with back pain and arthritis. The three arms in the trial were; prescription strength lidocaine 5%, over the counter lidocaine 3.6%, menthol 1.25% and placebo.
New Formulation	NCT04026945 ↗	Sustained Release Lidocaine for Treatment of Scrotal Pain	Completed	University of British Columbia	Phase 1/Phase 2	2019-10-31	In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated.
New Formulation	NCT05193227 ↗	Sustained Release Lidocaine for the Treatment of Postoperative Pain	Recruiting	University of British Columbia	Phase 2	2021-10-27	In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing postoperative pain after pelvic surgery. The new formulation ST-01 is a sustained release lidocaine formulation and is expected to provide pain relief over multiple days. Currently, the drug lidocaine is not available as an injectable slow-release formulation.

All Clinical Trials for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001303 ↗	Effects of Endotoxin in Normal Human Volunteers	Completed	National Institutes of Health Clinical Center (CC)	Phase 1	1992-04-06	Bacterial infections can progress to a life-threatening illness called septic shock, characterized by low blood pressure and vital organ damage. The syndrome is thought to be caused by parts of the bacteria and by the body s own immune response to the infection. A major bacterial product that interacts with the immune defenses is called endotoxin. This study will examine the body s response to endotoxin in the lungs or bloodstream. When endotoxin is given in small amounts to humans, even though it is not an infection, it triggers a set of responses that are typical of what one would see with a true bacterial infection. This allows us to study the earliest changes in molecules and cells that are involved in some bacterial infections. This type of model is safe and has been used in humans for many years to understand the body s responses during infections. Normal volunteers 18 to 45 years of age may be eligible for this study. Candidates will have a history and physical examination, blood and urine tests, electrocardiogram (EKG) and chest X-ray. In addition, volunteers 40 to 45 years old will have an exercise stress test to screen for asymptomatic coronary artery disease. Participants will undergo one or more of the following procedures: Bronchoscopy, Bronchoalveolar Lavage, Bronchial Brushings, and Endobronchial Mucosal Biopsies: These techniques for examining lung function are used routinely in patient care and clinical research. The mouth and nasal and lung airways are numbed with an anesthetic. A bronchoscope (pencil-thin flexible tube) is then passed through the nose into the large airways of the lung. Cells and secretions from the airways are rinsed with salt water (bronchoalveolar lavage) and a flexible brush the size of a pencil tip is passed through the bronchoscope to scrape cells lining the airways. Lastly, pieces of tissue (the size of the ball of a ballpoint pen) lining the airways are removed for examination under the microscope. Intravenous Endotoxin: A small dose of endotoxin is injected into a vein. Blood samples are drawn at regular intervals for 8 hours after the injection and again after 1, 2, 3, 7 and 14 days to analyze the body s immune response to the bacteria in the blood. Instilled Endotoxin in the Lungs: A small amount (2 teaspoons) of salt water is squirted through a bronchoscope into a lobe of one lung, and then salt water containing a small dose of endotoxin is squirted into the other lung. Bronchial lavage, brushing, and biopsy (see above) are then done to study the response of the lung to the endotoxin. In addition, air is withdrawn through the bronchoscope to study air components from the lung that was instilled with salt water or endotoxin. Nitric Oxide Therapy: Endotoxin is instilled in a lung (see above) and then nitric oxide a colorless, odorless, tasteless gas mixed with room air in a concentration of 40 parts per million, is given through a cushioned mask placed over the mouth and nose. (Some participants will be given the nitric oxide mixture and others will breathe only room air through the mask to test the effects of the nitric oxide on the lung inflammation.) The mask will be worn continuously for 6 hours and removed before repeat bronchoscopy with lavage, brushing and biopsy. Some of the above procedures require placement of a catheter (thin plastic tube) in a wrist artery to monitor blood pressure from heartbeat to heartbeat and to collect blood samples. First, the skin is numbed with an anesthetic (lidocaine). A needle is then inserted into the artery, the catheter is slipped over the needle into the vessel, and the needle is removed.
NCT00001524 ↗	Thalidomide to Treat Oral Lesions in HIV-Infected Patients	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1996-06-01	This study will test the effectiveness of topical thalidomide in healing mouth sores in HIV infected patients. Oral (PO) thalidomide heals these sores at a dose of 200 mg per day. However, PO thalidomide can cause drowsiness, skin rashes, allergic reactions, increased viral load, and even nerve damage that may not be reversible. This study will evaluate the efficacy of a topical formulation of thalidomide (placed directly on the surface of the sore) for the healing of these sores. Persons with HIV infection of acquired immunodeficiency of at least 18 years of age with one or more chronic, painful intraoral lesions may be eligible for this study. Subjects must be referred by a primary care physician who is managing their care, and must have HIV/AIDS status confirmed. Patients' HIV treatment regimen will not be altered and those receiving highly active therapy will not be excluded. Patients will be excluded if they are concurrently being treated for mucosal lesions (including topical or systemic steroids, viscous lidocaine, topical or systemic anti-fungals, or mouthwashes), or concurrent thalidomide therapy; receving chemotherapy or radiation therapy for neoplasms; using concurrent acute therapy for opportunistic infections; concurrent use of sedatives (such as CNS depressants or alcohol use); history of allergy to thalidomide; pre-existing peripheral neuropathy of grade II or higher; pregnant or lactating females or those not practicing contraception according to FDA guidelines for thalidomide.
NCT00001724 ↗	Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1997-11-01	This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery.
NCT00001784 ↗	Mexiletine for the Treatment of Focal Dystonia	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1998-07-01	Dystonia refers to a condition characterized by involuntary muscle contractions that may cause pain, abnormal posture, or abnormal movements. The cause of dystonia is unknown, but some researchers believe it is a result of overactivity in the areas of the brain responsible for movement (basal ganglia). Lidocaine is a drug used for the treatment of irregular heartbeats. It is given by injection. Recent studies have shown that lidocaine is also effective for the treatment dystonia. Mexiletine is a drug similar to lidocaine used for irregular heartbeats that can be taken by mouth. Researchers would like to test the effectiveness of Mexiletine for the treatment of dystonia. Patients participating in the study will be divided into two groups; Group 1 will take Mexiletine for six weeks then stop. They will remain drug free for one week then begin taking a placebo "inactive sugar pill" for an additional six weeks. Group 2 will take a placebo "inactive sugar pill" for six weeks then stop. They will remain drug free for one week then begin taking a Mexiletine for an additional six weeks. Throughout the study researchers will test the effectiveness of the treatment by evaluating patients using clinical rating scales and neurophysiological studies. In addition, researchers will test patient's reflexes in an attempt to find out where mexiletine works in the nervous system.
NCT00002901 ↗	Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	Completed	National Cancer Institute (NCI)	Phase 1	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of docetaxel in treating patients with advanced solid tumors that have not responded to standard therapy or for which there is no effective therapy.
NCT00002901 ↗	Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	Completed	City of Hope Medical Center	Phase 1	1996-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of docetaxel in treating patients with advanced solid tumors that have not responded to standard therapy or for which there is no effective therapy.
NCT00006070 ↗	Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	2000-07-01	This study will evaluate the effects of the anti-inflammatory drug etanercept (Enbrel) on relieving pain and swelling after oral surgery. The Food and Drug Administration has approved Enbrel for treating symptoms of rheumatoid arthritis, including pain. Healthy volunteers 16 to 35 years of age who require third molar (wisdom teeth) extractions may be eligible for this study. Participants must not be allergic to aspirin or to non-steroidal anti-inflammatory drugs (NSAIDs). Candidates will be screened for eligibility with a medical history and oral examination, including X-rays if needed. Participation in the study requires four clinic visits: two for surgery and two for follow-up: Visit 1: Patients will have ultrasound pictures taken to measure cheek size. One hour before surgery, they will receive a dose of either 25 milligrams (mg) of Enbrel; 15 mg of the standard pain medicine Toradol; or a placebo (salt-water) through an arm vein. A local injection of an anesthetic (lidocaine) will be given before surgery to numb the mouth, and a sedative (Versed) will be infused through a vein to induce sleepiness. When the anesthetic takes effect, a small piece of tissue will be removed from the inside of the cheek, and then the upper and lower molars on one side of the mouth will be extracted. After surgery, a small piece of tubing will be placed in the lower extraction site, from which samples will be collected to measure chemicals involved in pain and inflammation. Patients will stay in the clinic for 4 hours after surgery while the anesthetic wears off and will complete pain questionnaires during that time. If, an hour after surgery, patients have pain that is not relieved by the treatment given before surgery, they may receive acetaminophen (Tylenol) and codeine for pain. Another biopsy will be taken (under local anesthetic) from the inside of the cheek when pain occurs or at the end of the 4-hour observation period. The tubing then will be removed and the patient discharged with Tylenol and codeine for pain. Visit 2: Patients will return to the clinic in the morning 48 hours after the oral surgery for a 1- to 2-hour visit. They will fill out questionnaires, undergo ultrasound imaging of both cheeks and have another biopsy taken from the inside of the cheek on the operated side. Visits 3 and 4: Three weeks after the first surgery patients will schedule extraction of the two wisdom teeth on the other side of the mouth, and the procedures for visits 1 and 2 will be repeated.

Clinical Trial Conditions for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

Condition Name

Condition Name for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Intervention	Trials
Pain	204
Postoperative Pain	91
Pain, Postoperative	80
Anesthesia	71

Condition MeSH

Condition MeSH for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Intervention	Trials
Pain, Postoperative	238
Neuralgia	56
Acute Pain	45
Agnosia	40

Clinical Trial Locations for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Location	Trials
Egypt	232
Canada	121
China	93
France	65
Brazil	54

Trials by US State

Trials by US State for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Location	Trials
California	127
New York	74
Pennsylvania	66
Texas	64
North Carolina	58

Clinical Trial Progress for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
PHASE4	74
PHASE3	32
PHASE2	39

Clinical Trial Status

Clinical Trial Status for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	1033
Recruiting	368
Unknown status	208

Clinical Trial Sponsors for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Sponsor	Trials
Assiut University	57
Cairo University	45
Ain Shams University	36

Sponsor Type

Sponsor Type for Lidocaine Hydrochloride 0.1% And Dextrose 5% In Plastic Container
Sponsor	Trials
Other	2346
Industry	221
U.S. Fed	49

Last updated: April 30, 2026

Clinical Trials Update, Market Analysis and Projections: Lidocaine Hydrochloride 0.1% and Dextrose 5% in Plastic Container

What is this product and how is it positioned clinically?

Lidocaine Hydrochloride 0.1% and Dextrose 5% in plastic container is a sterile, parenteral combination intended to deliver local anesthetic exposure (lidocaine HCl) in a dextrose (5%) solution vehicle. The drug is used in hospital settings where clinicians titrate lidocaine for analgesia/anesthesia objectives and use dextrose-containing fluid for compatibility and administration workflow.

Core product attributes (as typically marketed/handled in practice)

• Active: Lidocaine hydrochloride (0.1%)
• Vehicle: Dextrose 5%
• Packaging: Plastic container
• Administration setting: Clinical (hospital/acute care), infusion-based use patterns

No consolidated, mechanism-specific “clinical trials dataset” is identifiable from the prompt text alone. The rest of this brief therefore focuses on market structure, competitive dynamics, and projection logic that apply to established sterile IV anesthetic/adjunct products in plastic containers.

---

What does the clinical-trials landscape look like?

Phase-agnostic reality for this category Sterile lidocaine formulations in ready-to-administer containers are commonly maintained through:

• Branded label maintenance (safety/quality updates, packaging updates, stability extensions),
• Bioequivalence and formulation/packaging bridging when manufacturing sites or container types change,
• Post-authorization studies tied to pharmacovigilance, observational safety, and use-pattern documentation.

What you can infer for “clinical trials update”

• For a widely used, low-concentration lidocaine IV combination, sponsor-driven “new pivotal efficacy trials” are less common than regulatory-required bridging and post-market safety work.
• Trial activity, when present, typically clusters around:
  • container compatibility and stability (plastic container interactions),
  • manufacturing process changes and scale-up,
  • pharmacokinetic comparability after manufacturing/site changes.

What is missing in the request The prompt does not include:

• the regulatory origin (FDA NDA/ANDA/BLA vs international equivalents),
• specific product label indications,
• reference product name(s),
• or trial identifiers.

Per operating constraints, this prevents a complete, accurate, drug-specific clinical trials update (trial-by-trial listing, dates, endpoints, and results). The market and projection sections below proceed without claiming new trial outcomes.

---

How does the market work for lidocaine + dextrose sterile products?

Demand drivers

The demand for lidocaine-based sterile products in dextrose-containing IV solutions is driven by:

• Hospital utilization of local anesthetic-containing infusion protocols in perioperative and inpatient care pathways.
• Cost and workflow advantages of ready-to-administer formats in plastic containers (handling, storage, and pharmacy operations).
• Generic penetration: low-dose lidocaine combination products generally face strong generic manufacturing competition once regulatory exclusivities lapse.

Supply-side structure

Supply is typically split across:

• Originator/legacy manufacturers that maintain branded SKUs and label history,
• Generic and contract manufacturing entrants that win shelf space through price and reliable supply.

Plastic container packaging standards and stability data are gatekeeping factors for market access, especially when container types change.

---

Who are the likely competitors and how do they compete?

Competitors are typically other suppliers of:

• lidocaine hydrochloride sterile solutions (various strengths),
• lidocaine in combination vehicles,
• dextrose-containing lidocaine formulations,
• and substitutes where clinicians switch based on protocol.

Competition levers

1. Price per mL and per treatment course
2. Availability and lead times in hospitals and distributors
3. Container format (plastic vs glass), with emphasis on stability and compatibility
4. Regulatory interchangeability (generic status, labeling alignment)

Because the prompt does not name specific marketed brands, the analysis is framed at the competitive mechanism level rather than listing brand-level rivals.

---

Market size and forecast: what is the credible trajectory?

Forecast framework

Without product-specific trial/regulatory datapoints and without an explicit global reference product ID, a precise TAM/SAM model cannot be built to a credible number. What can be done is a defensible directional projection based on typical sterile IV anesthetic market behavior:

• Mature category: Mature hospital product class with steady baseline demand.
• Generic pressure: Downward price trend after generic entries.
• Volume stability: Volume tends to remain resilient because hospitals substitute within protocol constraints.
• Packaging and formulation continuity: Plastic container readiness reduces friction, supporting stable purchasing patterns.

Directional projection (base case)

• Revenue: Low-to-moderate growth in nominal terms, constrained by generics.
• Units: Stable or modest growth tied to inpatient procedure volume and protocol retention.
• Market share: Shifts toward suppliers with reliable plastic container supply chains and competitive contracting.

Outcome: Expect a steady market with price compression and volume resilience, not a high-growth profile.

---

What could change the outlook?

Key risk factors that can move revenue up or down:

Regulatory and supply

• Container-related stability or compatibility issues that force label changes or manufacturing shifts.
• Supply disruptions in sterile injectable manufacturing.
• Cost inflation in raw materials impacting pricing.

Clinical practice

• Protocol shifts away from lidocaine infusions in certain pathways.
• Uptake of alternative anesthetic strategies or formulations.

Commercial

• Distributor contracting cycles and group purchasing organization (GPO) bidding outcomes.
• Generic entry waves for lidocaine sterile combinations.

---

Commercial projection: scenario model

Base case (most likely for a mature sterile combination)

• Price: Gradual decline or stabilization due to generic competition
• Volume: Mild increase
• Net revenue: Low single-digit growth

Upside scenario

• Faster-than-expected uptake in perioperative/inpatient pathways
• No major supply disruptions
• Strong contracting positions for plastic-container supply

Result: mid single-digit nominal revenue growth.

Downside scenario

• Accelerated generic competition or price undercutting
• Supply constraints leading to lost contracts
• Clinical protocol substitution away from lidocaine infusions

Result: flat to negative nominal revenue growth.

---

Key regulatory and product constraints that matter

For lidocaine sterile IV products in plastic containers, the two practical constraints that shape market access are:

• Quality and stability in the specific plastic container configuration
• Label alignment and interchangeability that determine whether hospitals can switch suppliers without protocol re-qualification

These factors influence both procurement and the timeline of market share capture for generic entrants.

---

Key Takeaways

• Lidocaine Hydrochloride 0.1% and Dextrose 5% in plastic container is a mature, hospital-focused sterile injectable product category with demand tied to inpatient and perioperative protocols.
• A precise, trial-by-trial “clinical trials update” cannot be produced from the prompt because no drug-specific trial identifiers, regulatory references, or label indications are provided.
• Market outlook is structurally characterized by generic pressure, stable hospital volume consumption, and packaging-driven supply reliability.
• Projections should be treated as steady-to-low-growth in nominal revenue with price compression and limited volatility, absent container-related or supply-chain disruptions.

---

FAQs

1. Is lidocaine HCl 0.1% with dextrose 5% considered a high-growth product?
   No. The product category is typically mature with generic competition, driving price compression and limiting revenue growth.

2. What most influences hospital purchasing for plastic-container sterile lidocaine products?
   Contract pricing, supply reliability, container-related stability/compatibility, and label interchangeability.

3. Do companies still run major Phase 3 trials for this kind of sterile formulation?
   Often not. Activity usually shifts to stability, packaging bridging, bioequivalence, and post-market safety work unless a new indication is pursued.

4. What is the biggest downside risk to revenue?
   Accelerated generic undercutting, supply interruptions, or container/stability issues that disrupt procurement.

5. What is the most likely projection range?
   Nominal revenue growth is typically low single digits in base case due to stable demand offset by price declines.

---

References

[1] (No citable sources provided in the prompt; no article, label, registry record, or market dataset was supplied to support drug-specific clinical trials or numeric market sizing.)